Whittier Trust Co. of Nevada Inc. Acquires 761 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Whittier Trust Co. of Nevada Inc. grew its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 3.7% during the 3rd quarter, Holdings Channel.com reports. The firm owned 21,331 shares of the medical instruments supplier’s stock after purchasing an additional 761 shares during the period. Whittier Trust Co. of Nevada Inc.’s holdings in West Pharmaceutical Services were worth $6,402,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the business. Whittier Trust Co. grew its stake in West Pharmaceutical Services by 4.4% during the 3rd quarter. Whittier Trust Co. now owns 41,804 shares of the medical instruments supplier’s stock worth $12,547,000 after buying an additional 1,779 shares during the last quarter. Northwest Investment Counselors LLC purchased a new position in shares of West Pharmaceutical Services in the 3rd quarter valued at approximately $30,000. Vest Financial LLC grew its holdings in shares of West Pharmaceutical Services by 31.0% during the third quarter. Vest Financial LLC now owns 151,217 shares of the medical instruments supplier’s stock valued at $45,389,000 after buying an additional 35,771 shares during the last quarter. Harfst & Associates Inc. increased its position in shares of West Pharmaceutical Services by 7.9% in the 3rd quarter. Harfst & Associates Inc. now owns 7,484 shares of the medical instruments supplier’s stock valued at $2,246,000 after acquiring an additional 551 shares during the period. Finally, Mitsubishi UFJ Asset Management UK Ltd. raised its stake in West Pharmaceutical Services by 200.0% in the 3rd quarter. Mitsubishi UFJ Asset Management UK Ltd. now owns 6,000 shares of the medical instruments supplier’s stock worth $1,801,000 after acquiring an additional 4,000 shares during the last quarter. 93.90% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares of the company’s stock, valued at approximately $443,400. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.53% of the stock is currently owned by company insiders.

West Pharmaceutical Services Stock Performance

Shares of WST stock traded down $5.56 during mid-day trading on Monday, reaching $287.76. The stock had a trading volume of 175,041 shares, compared to its average volume of 550,030. The business’s fifty day moving average is $299.96 and its 200-day moving average is $324.52. The firm has a market cap of $20.87 billion, a price-to-earnings ratio of 41.08, a PEG ratio of 10.46 and a beta of 1.01. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03.

West Pharmaceutical Services (NYSE:WST) last posted its earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a return on equity of 19.17% and a net margin of 18.25%. The firm had revenue of $702.10 million for the quarter, compared to analysts’ expectations of $729.36 million. During the same period in the previous year, the company earned $2.11 earnings per share. The company’s revenue was down 6.9% compared to the same quarter last year. On average, research analysts forecast that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.